[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 13 of about 13
1. Székely B, Langmár Z, Somlai K, Szentmártoni G, Szalay K, Korompay A, Szász AM, Kulka J, Bánhidy F, Dank M: [Treatment of pregnancy associated breast cancer]. Orv Hetil; 2010 Aug 8;151(32):1299-303
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of pregnancy associated breast cancer].
  • Pregnancy-associated breast cancer (PABC) is defined as cancer of the breast diagnosed during pregnancy and up to 1 year postpartum.
  • Young patients with PABC do not have worse prognosis compared with those with non-PABC; however, pregnancy can contribute to a delay in breast cancer diagnosis, evaluation, and treatment.
  • Primary care physicians and gynecologists should be careful in the thorough workup of breast symptoms in the pregnant population to expedite diagnosis and allow multidisciplinary treatment as early as possible following the established diagnosis.
  • Authors report a case of a 30-year-old pregnant woman, who detected inflammatory signs of her right breast and a palpable axillary mass at the 21st week of gestation.
  • Therefore fine needle aspiration biopsy of the axillary lump was performed, with the result of unequivocal diagnosis of metastatic invasive carcinoma.
  • The patient was referred to the multidisciplinary tumor board of our Department at the 27st week of gestation with the symptoms of inflammatory breast cancer, palpable right axillary and supraclavicular lymph nodes.
  • Core biopsy showed an ER and PR negative, Her-2 positive, grade 3, infiltrating ductal carcinoma of the breast.
  • After radiotherapy, trastuzumab medication was initiated.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / therapy. Carcinoma, Ductal, Breast / therapy. Pregnancy Complications, Neoplastic / therapy


2. Papantoniou V, Christodoulidou J, Papadaki E, Valotassiou V, Stipsanelli A, Louvrou A, Lazaris D, Sotiropoulou M, Pampouras G, Keramopoulos A, Michalas S, Zerva C: 99mTc-(V)DMSA scintimammography in the assessment of breast lesions: comparative study with 99mTc-MIBI. Eur J Nucl Med; 2001 Jul;28(7):923-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 99mTc-(V)DMSA scintimammography in the assessment of breast lesions: comparative study with 99mTc-MIBI.
  • The purpose of this study was to evaluate and compare the diagnostic accuracy of pentavalent technetium-99m dimercaptosuccinic acid [99mTc-(V)DMSA] and 99mTc-methoxyisobutylisonitrile (MIBI) in the detection of primary breast cancer and metastatic lymph node involvement, and in the clarification of cases with indeterminate mammograms.
  • Forty-one women (mean age+/-SD 55+/-7 years) referred for a suspicious breast lesion on physical examination and/or an abnormal mammogram underwent MIBI and (V)DMSA scintimammography (SMM) at separate sessions (48-h interval).
  • Lateral prone and anterior supine images were obtained at 10 and 60 min after administration of 740-925 MBq of each tracer, in the arm contralateral to the breast lesion.
  • Breast cancer was histologically confirmed in 26 patients (mean diameter+/-SD 2.87+/-1.5 cm).
  • Mammography was definitely positive in 23/26 patients with breast cancer and indeterminate in 3/26 (sensitivity 88.4%).
  • Both MIBI and (V)DMSA SMM detected 23/26 breast cancers (sensitivity 88.4%) and were true negative in 14/15 (specificity 93.3%).
  • T/B ratios for breast cancer in MIBI and (V)DMSA scans were similar, and significantly higher than for benign lesions.
  • In addition, (V)DMSA detected seven of eight cases of in situ ductal carcinoma (DCIS) associated with infiltrating carcinomas, while MIBI detected only two of these eight cases. (V)DSMA was also diffusely concentrated in benign lesions complicated by epithelial hyperplasia.
  • Metastatic lymph node involvement was successfully imaged in 15/19 patients with metastatic disease by both agents (sensitivity 78.9%), while true-negative scans were observed in 19/22 (specificity 86.3%) patients with benign or malignant tumours without lymph node metastases.
  • We conclude that both (V)DMSA and MIBI show an excellent ability to detect breast cancer and its lymph node metastases. (V)DMSA also has a tendency to be diffusely and more intensely localised than MIBI in pre-invasive lesions, such as DCIS or epitheliosis, which are at risk of developing into malignancies. (V)DMSA could therefore provide a useful tool in the diagnosis of such lesions and possibly modify a predefined surgical plan.
  • [MeSH-major] Breast / radionuclide imaging. Breast Neoplasms / radionuclide imaging. Radiopharmaceuticals. Technetium Tc 99m Dimercaptosuccinic Acid. Technetium Tc 99m Sestamibi
  • [MeSH-minor] Carcinoma, Ductal, Breast / radionuclide imaging. Carcinoma, Intraductal, Noninfiltrating / radionuclide imaging. Female. Humans. Lymph Nodes / radionuclide imaging. Lymphatic Metastasis. Mammography. Middle Aged. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11504092.001).
  • [ISSN] 0340-6997
  • [Journal-full-title] European journal of nuclear medicine
  • [ISO-abbreviation] Eur J Nucl Med
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 494JNQ8L28 / Technetium Tc 99m Dimercaptosuccinic Acid; 971Z4W1S09 / Technetium Tc 99m Sestamibi
  •  go-up   go-down


3. Mathews MS, Linskey ME, Hasso AN, Fruehauf JP: The effect of bevacizumab (Avastin) on neuroimaging of brain metastases. Surg Neurol; 2008 Dec;70(6):649-52; discussion 653
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Bevacizumab is FDA approved to treat colon cancer and is currently used off label for metastatic breast, kidney, and lung cancers.
  • CASE DESCRIPTION: The authors report the case of a 54-year-old woman with metastatic infiltrating ductal breast carcinoma who developed left occipital and right parietal intraaxial contrast-enhancing masses on surveillance magnetic resonance imaging (MRI).
  • Histopathologic examination was consistent with metastatic breast cancer indistinguishable from her previously resected enhancing brain metastasis.
  • CONCLUSION: This case is unique in that we have neuroimaging on prebevacizumab, concurrent bevacizumab, and postbevacizumab brain metastases in the same patient with a single cancer primary, thus, assuring that alterations in neuroimaging characteristics are consistent with bevacizumab effect.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antibodies, Monoclonal / therapeutic use. Brain Neoplasms / drug therapy. Brain Neoplasms / secondary. Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Ductal, Breast / secondary
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Bevacizumab. Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Female. Humans. Magnetic Resonance Imaging. Middle Aged

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18261776.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


Advertisement
4. Ren Y, Wu L, Frost AR, Grizzle W, Cao X, Wan M: Dual effects of TGF-beta on ERalpha-mediated estrogenic transcriptional activity in breast cancer. Mol Cancer; 2009 Nov 27;8:111
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dual effects of TGF-beta on ERalpha-mediated estrogenic transcriptional activity in breast cancer.
  • BACKGROUND: TGF-beta resistance often develops in breast cancer cells that in turn overproduce this cytokine to create a local immunosuppressive environment that fosters tumor growth and exacerbates the invasive and metastatic behavior of the tumor cells themselves.
  • Smads-mediated cross-talk with the estrogen receptor has been implied to play an important role in development and/or progression of breast cancer.
  • We investigated how TGF-beta regulates ERalpha-induced gene transcription and potential mechanisms of frequent TGF-beta resistance in breast cancer.
  • METHODS: Effect of TGF-beta on ERalpha-mediated gene transcription was investigated in breast cancer cell lines using transient transfection, real-time PCR, sequential DNA precipitation, and small interfering RNA assays.
  • The expression of Smads on both human breast cancer cell lines and ERalpha-positive human breast cancer tissue was evaluated by immunofluorescence and immunohistochemical assays.
  • RESULTS: A complex of Smad3/4 mediates TGF-beta inhibition of ERalpha-mediated estrogenic activity of gene transcription in breast cancer cells, and Smad4 is essential and sufficient for such repression.
  • Down-regulation and abnormal cellular distribution of Smad4 were associated with some ERalpha-positive infiltrating human breast carcinoma.
  • There appears a dynamic change of Smad4 expression from benign breast ductal tissue to infiltrating ductal carcinoma.
  • CONCLUSION: These results suggest that aberrant expression of Smad4 or disruption of Smad4 activity lead to the loss of TGF-beta suppression of ERalpha transactivity in breast cancer cells.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Oncol. 2008 Apr;32(4):791-6 [18360706.001]
  • [Cites] Breast Cancer Res. 2007;9(4):305 [17705882.001]
  • [Cites] Cell Oncol. 2008;30(4):337-47 [18607068.001]
  • [Cites] Cells Tissues Organs. 2008;188(1-2):225-35 [18303245.001]
  • [Cites] Hum Mutat. 2009 Feb;30(2):E451-9 [19058223.001]
  • [Cites] Breast Cancer Res. 2009;11(1):202 [19291273.001]
  • [Cites] Exp Mol Pathol. 2009 Aug;87(1):48-53 [19341727.001]
  • [Cites] Nat Cell Biol. 2001 Jun;3(6):587-95 [11389444.001]
  • [Cites] J Biol Chem. 2001 Nov 16;276(46):42908-14 [11555647.001]
  • [Cites] Cancer Res. 2002 Jan 15;62(2):497-505 [11809701.001]
  • [Cites] Endocrinology. 2002 Jul;143(7):2635-42 [12072396.001]
  • [Cites] Cell. 2002 Jul 12;110(1):19-32 [12150994.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):1034-9 [12552124.001]
  • [Cites] J Biol Chem. 2003 Apr 25;278(17):15192-200 [12576474.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Jul 11;306(4):799-804 [12821112.001]
  • [Cites] Development. 2003 Dec;130(24):6143-53 [14597578.001]
  • [Cites] Mol Endocrinol. 2004 Jul;18(7):1643-57 [15056732.001]
  • [Cites] Cancer Res. 1990 Jan 15;50(2):299-303 [2295070.001]
  • [Cites] Mol Cell Endocrinol. 1993 Nov;97(1-2):115-23 [8143893.001]
  • [Cites] J Clin Oncol. 1995 Feb;13(2):513-29 [7844613.001]
  • [Cites] J Cell Biochem. 1996 Apr;61(1):9-17 [8726350.001]
  • [Cites] J Biol Chem. 1998 Mar 27;273(13):7749-56 [9516484.001]
  • [Cites] Int J Cancer. 1999 Mar 31;81(1):98-103 [10077159.001]
  • [Cites] Oncogene. 1999 Aug 26;18(34):4879-83 [10490821.001]
  • [Cites] N Engl J Med. 2005 Jan 20;352(3):254-66 [15659725.001]
  • [Cites] Clin Cancer Res. 2005 Jan 15;11(2 Pt 2):937s-43s [15701890.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Apr;42(4):372-83 [15645498.001]
  • [Cites] Breast Cancer Res. 2005;7(5):R753-64 [16168121.001]
  • [Cites] JAMA. 2005 Oct 5;294(13):1634-46 [16204663.001]
  • [Cites] Annu Rev Cell Dev Biol. 2005;21:659-93 [16212511.001]
  • [Cites] Cancer Res. 2006 Mar 15;66(6):3044-50 [16540653.001]
  • [Cites] BMC Cancer. 2006;6:25 [16438724.001]
  • [Cites] Cancer Biol Ther. 2006 Jun;5(6):601-7 [16627986.001]
  • [Cites] Hum Mutat. 2006 Sep;27(9):897-905 [16865698.001]
  • [Cites] Cell Biochem Biophys. 2006;46(1):79-90 [16943625.001]
  • [Cites] Carcinogenesis. 2006 Nov;27(11):2148-56 [16698802.001]
  • [Cites] J Exp Clin Cancer Res. 2006 Sep;25(3):433-42 [17167985.001]
  • [Cites] Ann N Y Acad Sci. 2006 Nov;1089:119-26 [17261761.001]
  • [Cites] J Pathol. 2007 Apr;211(5):499-506 [17236182.001]
  • [Cites] Nat Genet. 2007 May;39(5):655-60 [17417639.001]
  • [Cites] Front Biosci. 2007;12:4393-401 [17485383.001]
  • [Cites] Exp Mol Pathol. 2007 Jun;82(3):284-91 [17289018.001]
  • [Cites] Physiol Rev. 2007 Jul;87(3):905-31 [17615392.001]
  • [Cites] Prostate. 2008 May 1;68(6):661-74 [18213629.001]
  • (PMID = 19943940.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / DK60913
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Estrogen Receptor alpha; 0 / Estrogens; 0 / Smad3 Protein; 0 / Smad4 Protein; 0 / Transforming Growth Factor beta
  • [Other-IDs] NLM/ PMC2787496
  •  go-up   go-down


5. Hathout Y, Gehrmann ML, Chertov A, Fenselau C: Proteomic phenotyping: metastatic and invasive breast cancer. Cancer Lett; 2004 Jul 16;210(2):245-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteomic phenotyping: metastatic and invasive breast cancer.
  • The adriamycin resistant breast cancer cell line (MCF-7/ADR) is a subject of ongoing debate concerning its origin and or source.
  • Previous studies in our laboratory showed that MCF-7/ADR has a unique cytosolic protein expression pattern when compared to that of the parental MCF-7 cell line and other drug resistant MCF-7 cell lines.
  • Protein expression patterns obtained using two-dimensional gel electrophoresis and mass spectrometry indicated that this MCF-7/ADR cell line shares some similarities with the metastatic breast cancer cell lines MDA-MB.
  • Further comparisons with available two-dimensional gel electrophoresis maps in the literature indicate that MCF-7/ADR has a protein expression signature even closer to of the ductal infiltrating breast carcinoma cell line 8701.
  • These observations suggest that MCF-7/ADR cells might have originated in a selection of ductal infiltrating carcinoma cells, which were present among the original MCF-7 cell population.
  • These ductal infiltrating carcinoma cells may possess an intrinsic adriamycin resistance phenotype.
  • [MeSH-major] Antibiotics, Antineoplastic / pharmacology. Breast Neoplasms / genetics. Breast Neoplasms / pathology. Carcinoma, Ductal / genetics. Carcinoma, Ductal / pathology. Doxorubicin / pharmacology. Neoplasm Invasiveness. Neoplasm Metastasis. Proteomics
  • [MeSH-minor] Drug Resistance, Neoplasm / genetics. Electrophoresis, Gel, Two-Dimensional. Female. Humans. Phenotype. Tumor Cells, Cultured


6. Afsar NA, Kulsoom B, Mateen A, Ahmed S, Tahseen M, Ahmed A: Breast cancer pattern and chemotherapy response--an institutional study in Pakistan. Asian Pac J Cancer Prev; 2010;11(3):825-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast cancer pattern and chemotherapy response--an institutional study in Pakistan.
  • BACKGROUND: This study was planned to audit female breast cancers and their chemotherapy in a busy public sector institution.
  • METHOD: Retrospective analysis of the records at Karachi Institute of Radiotherapy and Nuclear Medicine.
  • RESULTS: A total of 3,431 female breast cancer patients presented during 2001-2008, half being <45 years, mostly suffering from infiltrating ductal carcinoma of breast.
  • The low grade tumors showed a two-fold likelihood of ER and PR positivity as compared to high grade lesions.
  • CONCLUSIONS: Infiltrating ductal carcinoma of the breast is the most common type.
  • Tendency for late diagnosis, metastatic disease, treatment failure as well as leukopenia especially in ≥ 45 years is present.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Lobular / drug therapy

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21039062.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


7. Jaukovic LDj, Ajdinovic BZ, Jankovic ZD, Strbac M: Technetium-99m-tetrofosmin in diagnosis of breast cancer and axillary lymph node involvement. Nucl Med Rev Cent East Eur; 2006;9(1):30-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Technetium-99m-tetrofosmin in diagnosis of breast cancer and axillary lymph node involvement.
  • BACKGROUND: The aim of this study was to evaluate the accuracy of breast cancer seeking agent Tc-99m-Tetrofosmin in the detection of breast malignancy and axillary lymph node metastases.
  • MATERIAL AND METHODS: Twenty-eight female patients (mean age 52.4) with 30 breast lesions suspected of malignancy were enrolled in the study.
  • RESULTS: SMM scans of 30 breast lesions were compared to the definitive histopathology findings (HP) using decision matrix.
  • In the group of 23 patients with positive SMM scans 19 had breast malignancy: 15 infiltrating ductal cancer, three patients with one infiltrating lobular, one papillary, one colloidal cancer and one patient with cystosarcoma phyllodes-malignant type.
  • SMM detected primary breast malignancy with 95% sensitivity, 60% specificity and 83% accuracy.
  • Metastatic involvement was confirmed by HP in 9 out of 20 patients.
  • CONCLUSION: Our results showed that SMM might be useful as a complementary test to improve the sensitivity and specificity of conventional imaging modalities, although SMM in the staging of breast carcinoma was less reliable.
  • Further studies to evaluate the role of SMM in metastatic node involvement are necessary.
  • [MeSH-major] Breast Neoplasms / diagnosis. Breast Neoplasms / radionuclide imaging. Lymphatic Metastasis / diagnosis. Lymphatic Metastasis / radionuclide imaging. Organophosphorus Compounds. Organotechnetium Compounds. Radiopharmaceuticals

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16791801.001).
  • [ISSN] 1506-9680
  • [Journal-full-title] Nuclear medicine review. Central & Eastern Europe
  • [ISO-abbreviation] Nucl Med Rev Cent East Eur
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Organophosphorus Compounds; 0 / Organotechnetium Compounds; 0 / Radiopharmaceuticals; 0 / technetium Tc 99m 1,2-bis(bis(2-ethoxyethyl)phosphino)ethane
  •  go-up   go-down


8. Uğur Y, Sari O, Uğur O, Korkusuz P, Varoğlu E, Arslan N, Gürcan N, Yildirim M, Sökmensüer C, Aşan E, Aras T: Lack of correlation between Tc-99m-sestaMIBI uptake and cadherin expression in infiltrating ductal breast carcinoma as prognostic indicators. Ann Nucl Med; 2003 Jun;17(4):281-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lack of correlation between Tc-99m-sestaMIBI uptake and cadherin expression in infiltrating ductal breast carcinoma as prognostic indicators.
  • Despite using various kinds of prognostic indicators, it is still not possible to predict the biological behavior of breast cancer in all patients.
  • Tc-99m-sestaMIBI (MIBI) uptake determined by breast scintigraphy and cadherin expression of tumor tissue revealed by immunohistochemistry are suggested as potential agents for this purpose.
  • The aim of this study was to assess the relationship between the degree of MIBI tumor uptake and cadherin expression in infiltrating ductal breast carcinoma.
  • Correlation with response to chemotherapy and some known prognostic factors of breast cancer such as tumor size, number of metastatic axillary lymph nodes and microscopic grading was also done.
  • Fourteen patients who underwent scintimammography and subsequent surgical excisional biopsy that revealed infiltrating ductal carcinoma were enrolled in this study.
  • Also, no statistically significant correlation was noted between MIBI uptake and tumor size, number of metastatic lymph nodes, microscopic grade, stage of the disease or response to chemotherapy.
  • Similarly, there was no statistically significant correlation between cadherin expression and tumor size, number of metastatic lymph nodes, microscopic grade, stage of the disease or chemotherapy response.
  • The results of this study imply that there is no correlation between MIBI tumor uptake and cadherin expression with neither of them good enough to be used as prognostic indicators for breast cancer.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Breast / radionuclide imaging. Breast Neoplasms / radionuclide imaging. Cadherins / metabolism. Carcinoma, Ductal / radionuclide imaging. Technetium Tc 99m Sestamibi

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12932110.001).
  • [ISSN] 0914-7187
  • [Journal-full-title] Annals of nuclear medicine
  • [ISO-abbreviation] Ann Nucl Med
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / Radiopharmaceuticals; 971Z4W1S09 / Technetium Tc 99m Sestamibi
  •  go-up   go-down


9. Ueyama Y, Yamamoto D, Yoshida H, Kanematsu S, Nakatake R, Kasahara N, Tanaka K, Shoji T, Okukawa H, Kwon AH: [A case of interstitial pneumonitis induced by S-1]. Gan To Kagaku Ryoho; 2010 Aug;37(8):1603-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • S-1, an oral fluoropyrimidine derivative, has been identified as an effective agent for the treatment of breast cancer.
  • A n 80-year-old woman was diagnosed with stage III infiltrating ductal carcinoma of the left breast and underwent a modified radical mastectomy in November 2001, followed by six courses of paclitaxel.
  • In October 2008, metastatic disease was detected in her skeletal system.
  • [MeSH-minor] Aged, 80 and over. Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Drug Combinations. Female. Humans. Neoplasm Metastasis / drug therapy. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Interstitial Lung Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20716897.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


10. Nagahama M, Sica DA: Pamidronate-induced kidney injury in a patient with metastatic breast cancer. Am J Med Sci; 2009 Sep;338(3):225-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pamidronate-induced kidney injury in a patient with metastatic breast cancer.
  • The American Society of Clinical Oncology recommends bisphosphonate use, such as intravenous pamidronate, for women with breast cancer who have radiographic evidence of bone destruction.
  • We present one such case of a patient who developed collapsing FSGS with nephrotic-range proteinuria after treatment with pamidronate for osteolytic bone metastases from an infiltrating ductal carcinoma of the breast.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Bone Neoplasms / prevention & control. Breast Neoplasms / drug therapy. Diphosphonates / adverse effects. Glomerulosclerosis, Focal Segmental / chemically induced. Glomerulosclerosis, Focal Segmental / diagnosis
  • [MeSH-minor] Aged. Apoptosis. Female. Humans. Mitochondria / drug effects


11. Norton L: Conceptual and practical implications of breast tissue geometry: toward a more effective, less toxic therapy. Oncologist; 2005 Jun-Jul;10(6):370-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conceptual and practical implications of breast tissue geometry: toward a more effective, less toxic therapy.
  • Breast tumor dimensions, as with all tissue dimensions in biology, can be calculated by fractals.
  • Fractal dimensions of infiltrating ductal adenocarcinomas of the breast are high (i.e., 2.98), which results in a very dense tissue compared with normal breast tissue (with a fractal dimension of about 2.25).
  • The reason for this high fractal dimension is that breast cancer can be considered as a conglomerate of many small Gompertzian tumors, each of which has a high cell density and hence ratio of mitosis to apoptosis.
  • Conventional thinking is that cancers metastasize because they are large, but in fact it may be that they are large because they are self-metastatic.
  • Many genes are associated with the biology of metastasis; these include: A) obligatory cancer genes (most of which regulate mitosis and mitotic rate);.
  • B) genes relating to self-metastasis and growth of tumors at local sites, conferring the ability to invade and grow with high cell density; and C) genes that relate to the ability of the cancer to metastasize to distant areas.
  • Additionally, fibroblasts may send out abnormal growth signals causing abnormal breast tissue growth.
  • Consequently, we are not only dealing with abnormal cancer cells, but also with the tissue that surrounds them, or the microenvironment, that is, the "Smith-Bissell" model.
  • [MeSH-major] Breast Neoplasms / pathology. Disease Progression. Models, Biological. Neoplasm Metastasis / pathology. Neoplastic Stem Cells
  • [MeSH-minor] Antineoplastic Agents / administration & dosage. Antineoplastic Agents / pharmacokinetics. Antineoplastic Agents / therapeutic use. Cell Proliferation / drug effects. Female. Granulocyte Colony-Stimulating Factor / therapeutic use. History, 19th Century. History, 20th Century. History, 21st Century. Humans. Recombinant Proteins. Stem Cells

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Oncologist. 2005 Jun-Jul;10(6):369 [15967830.001]
  • (PMID = 15967831.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Historical Article; Journal Article; Portraits
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Recombinant Proteins; 143011-72-7 / Granulocyte Colony-Stimulating Factor
  •  go-up   go-down


12. Huang F, Kushner YB, Langleben A, Foulkes WD: Eleven years disease-free: role of chemotherapy in metastatic BRCA2-related breast cancer. Nat Rev Clin Oncol; 2009 Aug;6(8):488-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Eleven years disease-free: role of chemotherapy in metastatic BRCA2-related breast cancer.
  • BACKGROUND: Infiltrating ductal carcinoma of the breast, staged as pT1N3, was diagnosed in a 41-year-old premenopausal French-Canadian woman.
  • Upon full remission, protocol-mandated locoregional breast and prophylactic cranial radiation was delivered.
  • DIAGNOSIS: A BRCA2 8765delAG mutation was identified, in the context of unusual and sustained complete remission from widely metastatic breast cancer.
  • MANAGEMENT: The patient is now followed at a multidisciplinary high-risk prevention clinic because BRCA2 mutations are associated with increased risk of ovarian and breast cancers.
  • This case supports the possibility of differential treatment response in BRCA2-positive breast cancer, although this remains to be conclusively demonstrated.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Carcinoma, Ductal, Breast / secondary. Genes, BRCA2
  • [MeSH-minor] Adult. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Combined Modality Therapy. Female. Humans. Lymphatic Metastasis. Mastectomy, Segmental. Pedigree. Transplantation, Autologous


13. Luján B, Carrera D, Picas J, Izquierdo V, Siurana R, Quintero L, Martínez de Vírgala C: [Detection of contralateral axillary sentinel lymph node by lymphoscintigraphy in breast cancer: prognostic implications]. Rev Esp Med Nucl; 2010 May-Jun;29(3):135-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Detection of contralateral axillary sentinel lymph node by lymphoscintigraphy in breast cancer: prognostic implications].
  • [Transliterated title] Visualización de ganglio centinela axilar contralateral por linfogammagrafía en cáncer de mama: implicaciones pronósticas.
  • The role of nuclear medicine in the detection of sentinel lymph nodes (SLNs) in primary breast cancer is very useful to determine regional lymphatic drainage from the affected breast, mainly its anatomical and/or tumoral individual variability and to determine the initial tumor stage.
  • We present the case of an infiltrating ductal carcinoma of the breast (T2) in the junction of the inner quadrants of the right breast studied by lymphoscintigraphy and gamma probe detection.
  • Three non-metastatic sentinel lymph nodes were found with the selective lymphadenectomy: two in the ipsilateral axilla and one in the contralateral axilla.
  • The lymphoscintigraphic finding of the axillary sentinel lymph node contralateral to the affected breast demonstrates the individual anatomical variability in mammary drainage.
  • It emphasizes the importance of nuclear medicine imaging techniques in its detection and generates new prognostic approaches with impact on therapeutic measures and patient follow-up.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / secondary. Sentinel Lymph Node Biopsy
  • [MeSH-minor] Aged. Axilla. Breast / anatomy & histology. Female. Humans. Lymph Node Excision. Lymphatic Metastasis. Lymphatic System / anatomy & histology. Mastectomy, Segmental. Prognosis. Radiology, Interventional. Radiopharmaceuticals / administration & dosage. Technetium Tc 99m Aggregated Albumin / administration & dosage

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 Elsevier España, S.L. y SEMNIM. All rights reserved.
  • (PMID = 20398968.001).
  • [ISSN] 0212-6982
  • [Journal-full-title] Revista española de medicina nuclear
  • [ISO-abbreviation] Rev Esp Med Nucl
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0 / Technetium Tc 99m Aggregated Albumin; 0 / technetium Tc 99m nanocolloid
  •  go-up   go-down






Advertisement